FDA Officials Why a Rare Complication is Causing Pause of Johnson & Johnson Vaccine

Dr. Janet Woodcock, M.D., Acting Chairperson of the U.S. Food and Drug Administration and Dr. Peter Marks, M.D., Ph.D., explained that the rare blood clots’ patterned combination with low platelet levels is of concern to the F.D.A. and the Centers for Disease Control and Prevention (C.D.C.), which is why a temporary pause on Johnson & Johnson vaccine rollout has been requested in order for the federal medical community to ensure that this issue is not more common than is currently known and to alert primary care providers on symptoms to be watching out for in patients recently vaccinated with the Johnson & Johnson COVID-19 vaccine.

Stay up to date with our videos by subscribing to our channel: https://www.youtube.com/user/CivicCenterTV15?sub_confirmation=1.
Visit our website for more information on the Megacast and Coronavirus: https://civiccentertv.michigandigital.com/
Follow us ⬇ ⬇
• https://www.youtube.com/user/CivicCenterTV15
• https://www.facebook.com/civiccentertv15/
• https://twitter.com/CivicCenterTV
• https://www.instagram.com/civiccentertv/